BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Interest Income
Income earned on cash, deposits, and investments held by the company.
BioAge Labs, Inc.NASDAQ: BIOA
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income dips below year-ago levels
Q1 FY2026 interest income of $3.27M fell 12.0% year over year, behind the +4.9% change in trailing-twelve-month interest income. Sequentially, it rose 17.0% from the prior quarter. Over 3 fiscal years it compounded at +204.2% a year.
Context
- Interest income amounted to 145.5% of revenue in FY2025.
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -12.0% toward the trailing-twelve-month pace of +4.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 13.09M USD
- Year-over-year change
- +35.9%
- 3-year CAGR
- +204.2%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.09M | +35.9% |
| FY2024 | 2024-12-31 | 9.63M | +296.1% |
| FY2023 | 2023-12-31 | 2.43M | +422.8% |
| FY2022 | 2022-12-31 | 465K | — |
Interest Income vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +4.9% is the 2nd highest of 8, against a peer median of -39.6%.
- Interest income amounts to 122.5% of revenue for BIOA, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.35M USD | -14.3% | +61.7% | — | |
| LTM Mar 2026 | $14.02M USD | -40.6% | +13.7% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $12.64M USD | +4.9% | +204.2% | 122.5% |
| LTM Mar 2026 | CA$11.15M CAD | +26.5% | -25.6% | 3.6% | |
| LTM Mar 2026 | CA$6.6M CAD | -42.6% | -32.4% | 2.1% | |
| LTM Mar 2026 | $5.62M USD | -34.1% | +73.0% | — | |
| LTM Mar 2026 | $2.26M USD | -39.6% | -0.5% | 111.9% | |
| LTM Mar 2026 | $401K USD | — | — | 0.3% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | -$1.51M USD | -112.9% | +14.6% | 3.9% | |
| Peer median (excluding BIOA) | — | -39.6% | +13.7% | 2.8% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 9M |
| Gross Margin | — | — | — | 100.0% |
| Research & Development | 30.52M | 33.89M | 59.04M | 73.97M |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M | 27.81M |
| Operating Expenses | 39.97M | 48.4M | 78.19M | 101.78M |
| Depreciation & Amortization | 129K | 162K | 167K | 213K |
| EBITDA | (39.35M) | (55.9M) | (68.58M) | (79.7M) |
| EBITDA Margin | — | — | — | -886.0% |
| Operating Income | (39.97M) | (48.4M) | (78.19M) | (92.78M) |
| Operating Margin | — | — | — | -1031.5% |
| Interest Income | 465K | 2.43M | 9.63M | 13.09M |
| Interest Expense | 241K | 7.79M | 2.37M | 697K |
| Other Income / Expenses | 247K | (15.45M) | 7.09M | 12.18M |
| Income Before Tax | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Pre-Tax Margin | — | — | — | -896.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Net Margin | — | — | — | -896.1% |
| EPS (Basic) | (1.16) | (1.87) | (1.98) | (2.24) |
| EPS (Diluted) | (1.16) | (1.87) | (1.98) | (2.24) |
| Weighted Avg Shares | 34.17M | 34.2M | 35.85M | 35.93M |
| Weighted Avg Shares (Diluted) | 34.17M | 34.2M | 35.85M | 35.93M |
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.